Bispecific antibodies are showing unprecedented single agent activity in relapsed/refractory MM. There are several phase I trials in this setting, let’s see at the data shared at #ASCO22 and #EHA2022 with Teclistamab , Elranatamab and REGN5458 targeting BCMA and…
….Talquetamab targeting GPRC5D. Here is a quick summary of the data #CARTSM #ASCO22_SZU #MedIQ22ASCO Strong work by #mmsm peeps!!
Teclistamab SC showed a response rate of 63%, MRD- 27% at 10-5 via NGS, CRS ~70% (grade 1/2), ICANS 3 % (grade 1/2),median PFS 11.3 months, median DoR 18.4 months, median follow-up 14 months. ascopubs.org/doi/abs/10.120… #CARTSM #ASCO22 #ASCO22_SZU #MedIQ22ASCO #EHA2022
Teclistamab SC combined with Daratumumab SC, weekly/q2 weekly dosing schedules, shows a response rate 78%, MRD- 27% at 10-5 via NGS, CRS ~61% (grade 1/2), median follow-up of 7.2 months. library.ehaweb.org/eha/2022/eha20… #CARTSM #ASCO22 #ASCO22_SZU #MedIQ22ASCO #EHA2022
In BCMA exposed/refractory MM (n=40), Teclistamab SC shows a response rate 52.5%, MRD- 17.5% at 10-5 via NGS, CRS ~70% (grade 1/2), 15/21 responders maintaining response at a median follow-up 11.8 months ascopubs.org/doi/abs/10.120… #CARTSM #ASCO22 #ASCO22_SZU #MedIQ22ASCO #EHA2022
Elranatamab SC shows a response rate 54%, CRS ~67% (grade 1/2), median PFS not reached at a median follow-up of 8.1 months ascopubs.org/doi/abs/10.120… #CARTSM #ASCO22 #ASCO22_SZU #MedIQ22ASCO #EHA2022
In BCMA exposed/refractory MM, Elranatamab SC shows a response rate ~60%, CRS ~59% (grade 1/2), ICANS in 3.6% (grade 1/2), median follow-up ~4 months. ascopubs.org/doi/abs/10.120… #CARTSM #ASCO22 #ASCO22_SZU #MedIQ22ASCO #EHA2022
Talquetamab SC showed a response rate of 70%/64% across 2 doses (405 mcg/kg, 800 mcg/kg), MRD- 27% at 10-5 via NGS, CRS (77%/80%; grade 3: 3%/0%), Skin and nail related AEs 83%/75% of pts (grade 1/2) dysgeusia (63%/57%)median follow-up of 11.7 months. ascopubs.org/doi/abs/10.120…
Talquetamab SC combined with Daratumumab SC across two doses with weekly/q2 weekly dosing schedules, shows a response rate 76.5%, MRD- 27% at 10-5 via NGS, CRS ~65% (grade 1/2), dysgeusia 57%, median follow-up 4 months library.ehaweb.org/eha/2022/eha20… #CARTSM #MedIQ22ASCO #EHA2022
REGN5458 IV q 2 week showed a response rate of 50.7% overall, 75% in 200-800 mg dose group, lowest CRS amongst the bispecific antibodies so far ~38.4% (grade 1/2), median follow-up of 3 months library.ehaweb.org/eha/2022/eha20… #CARTSM #ASCO22 #ASCO22_SZU #MedIQ22ASCO #EHA2022
• • •
Missing some Tweet in this thread? You can try to
force a refresh
